Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetes
<p<Abstract</p< <p<Aim</p< <p<To assess the factors associated with antihyperglycaemic medication initiation in UK patients with newly diagnosed type 2 diabetes.</p< <p<Methods</p< <p<In a retrospective cohort study, patients with newly diagnosed type 2 diabetes were identified during the index period of 2003-2005. Eligible patients were ≥ 30 years old at the date of the first observed diabetes diagnosis (referred to as index date) and had at least 2 years of follow-up medical history (N = 9,158). Initiation of antihyperglycaemic medication (i.e., treatment) was assessed in the 2-year period following the index date. Adjusted Cox regression models were used to examine the association between time to medication initiation and patient age and other factors.</p< <p<Results</p< <p<Mean (SD) HbA<sub<1c </sub<at diagnosis was 8.1% (2.3). Overall, 51% of patients initiated antihyperglycaemic medication within 2 years (65%, 55%, 46% and 40% for patients in the 30- < 45, 45- < 65, 65- < 75, 75+ age groups, respectively). Among the treated patients, median (25<sup<th</sup<, 75<sup<th </sup<percentile) time to treatment initiation was 63 (8, 257) days. Of the patients with HbA<sub<1c </sub<≥ 7.5% at diagnosis, 87% initiated treatment within 2 years. These patients with a higher HbA<sub<1c </sub<also had shorter time to treatment initiation (adjusted hazard ratio (HR) = 2.44 [95% confidence interval (CI): 1.61, 3.70]; p < 0.0001). Increasing age (in years) was negatively associated with time to treatment initiation (HR = 0.98 [95% CI: 0.97, 0.99]; p < 0.001). Factors significantly associated with shorter time to treatment initiation included female gender and use of cardiovascular medications at baseline or initiated during follow up.</p< <p<Conclusions</p< <p<In this UK cohort of patients with newly diagnosed type 2 diabetes, only 51% had antihyperglycaemic medication initiated over a 2-year period following diagnosis. Older patients were significantly less likely to have been prescribed antihyperglycaemic medications. Elevated HbA<sub<1c </sub<was the strongest factor associated with initiating antihyperglycaemic medication in these patients.</p<.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
BMC Endocrine Disorders - 12(2012), 1, p 1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sinclair Alan J [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Age |
|---|
| doi: |
10.1186/1472-6823-12-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ065704282 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ065704282 | ||
| 003 | DE-627 | ||
| 005 | 20230502101610.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/1472-6823-12-1 |2 doi | |
| 035 | |a (DE-627)DOAJ065704282 | ||
| 035 | |a (DE-599)DOAJ1d31eab34d01466a8582931da2f59777 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC648-665 | |
| 100 | 0 | |a Sinclair Alan J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetes |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a <p<Abstract</p< <p<Aim</p< <p<To assess the factors associated with antihyperglycaemic medication initiation in UK patients with newly diagnosed type 2 diabetes.</p< <p<Methods</p< <p<In a retrospective cohort study, patients with newly diagnosed type 2 diabetes were identified during the index period of 2003-2005. Eligible patients were ≥ 30 years old at the date of the first observed diabetes diagnosis (referred to as index date) and had at least 2 years of follow-up medical history (N = 9,158). Initiation of antihyperglycaemic medication (i.e., treatment) was assessed in the 2-year period following the index date. Adjusted Cox regression models were used to examine the association between time to medication initiation and patient age and other factors.</p< <p<Results</p< <p<Mean (SD) HbA<sub<1c </sub<at diagnosis was 8.1% (2.3). Overall, 51% of patients initiated antihyperglycaemic medication within 2 years (65%, 55%, 46% and 40% for patients in the 30- < 45, 45- < 65, 65- < 75, 75+ age groups, respectively). Among the treated patients, median (25<sup<th</sup<, 75<sup<th </sup<percentile) time to treatment initiation was 63 (8, 257) days. Of the patients with HbA<sub<1c </sub<≥ 7.5% at diagnosis, 87% initiated treatment within 2 years. These patients with a higher HbA<sub<1c </sub<also had shorter time to treatment initiation (adjusted hazard ratio (HR) = 2.44 [95% confidence interval (CI): 1.61, 3.70]; p < 0.0001). Increasing age (in years) was negatively associated with time to treatment initiation (HR = 0.98 [95% CI: 0.97, 0.99]; p < 0.001). Factors significantly associated with shorter time to treatment initiation included female gender and use of cardiovascular medications at baseline or initiated during follow up.</p< <p<Conclusions</p< <p<In this UK cohort of patients with newly diagnosed type 2 diabetes, only 51% had antihyperglycaemic medication initiated over a 2-year period following diagnosis. Older patients were significantly less likely to have been prescribed antihyperglycaemic medications. Elevated HbA<sub<1c </sub<was the strongest factor associated with initiating antihyperglycaemic medication in these patients.</p< | ||
| 650 | 4 | |a Clinical inertia | |
| 650 | 4 | |a Age | |
| 650 | 4 | |a Type 2 diabetes mellitus | |
| 650 | 4 | |a Antihyperglycaemic medication | |
| 653 | 0 | |a Diseases of the endocrine glands. Clinical endocrinology | |
| 700 | 0 | |a Alexander Charles M |e verfasserin |4 aut | |
| 700 | 0 | |a Davies Michael J |e verfasserin |4 aut | |
| 700 | 0 | |a Zhao Changgeng |e verfasserin |4 aut | |
| 700 | 0 | |a Mavros Panagiotis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t BMC Endocrine Disorders |d BMC, 2003 |g 12(2012), 1, p 1 |w (DE-627)DOAJ000119881 |x 14726823 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2012 |g number:1, p 1 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/1472-6823-12-1 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/1d31eab34d01466a8582931da2f59777 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.biomedcentral.com/1472-6823/12/1 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1472-6823 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2012 |e 1, p 1 | ||